ALGENEX has developed two technology production platforms based on baculovirus vectors for the development of any recombinant protein (vaccines, diagnostic reagents and therapeutic proteins):
Baculovirus vector technologies accelerate the development times of any protein-based pharmaceutical or diagnostic product. Compared with traditional baculovirus-based production technologies, Algenex technologies are capable to increase production yields at unprecedented levels. Both technology platforms are highly robust for vaccine production and in particular for the production of proteins forming virus-like particles (VLP) to mimic the native structure of a virus, increasing the immune system recognition. Baculovirus vector technologies accelerate the development times of any protein-based pharmaceutical or diagnostic product. The ALGENEX’s technologies facilitate their scaling-up industrial production and reduce significantly the CAPEX and OPEX needed at development, clinical and industrial production phases .
ALGENEX has also developed and licensed immunopotentiating molecules like the targeting antibody APCH1 APC and the Sphere technology to particulate vaccine antigens. Both increase significantly the immune response against recombinant subunit monomeric vaccines.